Fentanyl and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-guided Superficial Cervical Plexus Block in Thyroid Surgeries

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
FentanylDexmedetomidineAdjuvantsBupivacaineUltrasoundSuperficial Cervical Plexus BlockThyroid Surgeries
Interventions
DRUG

Superficial cervical plexus block

Patients received superficial cervical plexus block with 1 ml of normal saline with 7ml bupivacaine 0.25% per side without adjuvants.

DRUG

Superficial cervical plexus block + Fentanyl

Patients received superficial cervical plexus block with fentanyl 1 ml (50 microgram) as an adjuvant to 7ml bupivacaine 0.25% per side.

DRUG

Superficial cervical plexus block + Dexmedetomidine

Patients received superficial cervical plexus block with dexmedetomidine 0.5mcg/kg in 1 ml of normal saline as an adjuvant to 7ml bupivacaine 0.25% per side.

Trial Locations (1)

33516

Kafr Elsheikh University, Kafr ash Shaykh

All Listed Sponsors
lead

Kafrelsheikh University

OTHER

NCT07057739 - Fentanyl and Dexmedetomidine as Adjuvants to Bupivacaine in Ultrasound-guided Superficial Cervical Plexus Block in Thyroid Surgeries | Biotech Hunter | Biotech Hunter